Specialists in biomolecules
One of our priorities is to improve the quality of life of the over 200 million patients in the world who suffer from osteoarthritis, joint lesions and muscular-skeletal disorders. Therefore, as well as Heparin, at Bioibérica we produce other glycosaminoglycans, like Chondroitin Sulfate, Glucosamine and Hyaluronic Acid, biomolecules indicated for the treatment of these illnesses.
A few years ago we thought it was time to innovate and step up research into new tools for the prevention, diagnosis and prognosis of osteoarthritis. We therefore made a strong commitment to personalized medicine and set out on projects in which we collaborate with recognized scientific entities. Genetic tests, biomarkers and cellular treatment are some of the lines of research we have up and running.
Approximately 28% of the world over 60s population have osteoarthritis and the increase in life expectancy and aging will mean that this disease will become the fourth highest cause of disability in the year 2020.
It is estimated that more than 15 million active people in Europe aged 40 to 65 years have joint pain. The corresponding figure in the United States is 19 millions.
We are looking for companies for licensing our products and achieve strategic agreements at international level. We offer a wide portfolio of products for osteoarthritis and joint health.